Novocure Ltd (NVCR) - Net Assets
Based on the latest financial reports, Novocure Ltd (NVCR) has net assets worth $330.72 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($787.93 Million) and total liabilities ($457.21 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Novocure Ltd (NVCR) tangible net worth to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $330.72 Million |
| % of Total Assets | 41.97% |
| Annual Growth Rate | 5.87% |
| 5-Year Change | -17.06% |
| 10-Year Change | 139.18% |
| Growth Volatility | 63.01 |
Novocure Ltd - Net Assets Trend (2013–2025)
This chart illustrates how Novocure Ltd's net assets have evolved over time, based on quarterly financial data. See how many days can Novocure Ltd fund operations to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Novocure Ltd (2013–2025)
The table below shows the annual net assets of Novocure Ltd from 2013 to 2025. For live valuation and market cap data, see Novocure Ltd (NVCR) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $340.47 Million | -5.47% |
| 2024-12-31 | $360.18 Million | -0.64% |
| 2023-12-31 | $362.50 Million | -17.83% |
| 2022-12-31 | $441.17 Million | +7.47% |
| 2021-12-31 | $410.49 Million | -13.86% |
| 2020-12-31 | $476.53 Million | +118.80% |
| 2019-12-31 | $217.79 Million | +94.01% |
| 2018-12-31 | $112.26 Million | -1.15% |
| 2017-12-31 | $113.56 Million | -20.22% |
| 2016-12-31 | $142.34 Million | -43.25% |
| 2015-12-31 | $250.82 Million | +156.27% |
| 2014-12-31 | $97.88 Million | -43.02% |
| 2013-12-31 | $171.78 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Novocure Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 109453900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Comprehensive Income | $-3.44 Million | -1.01% |
| Other Components | $1.63 Billion | 480.01% |
| Total Equity | $340.47 Million | 100.00% |
Novocure Ltd Competitors by Market Cap
The table below lists competitors of Novocure Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Guangdong Mingyang Electric Co. Ltd. A
SHE:301291
|
$1.95 Billion |
|
Atea ASA
OL:ATEA
|
$1.95 Billion |
|
Black Box Limited
NSE:BBOX
|
$1.95 Billion |
|
Twenty One Capital, Inc.
NYSE:XXI
|
$1.95 Billion |
|
Ahlatci Dogal Gaz Dagitim Enerji ve Yatirim A.S.
IS:AHGAZ
|
$1.95 Billion |
|
China Railway Group Limited
F:CNO
|
$1.95 Billion |
|
Dalian Bio-Chem Co Ltd
SHG:603360
|
$1.95 Billion |
|
NOS S.G.P.S. S.A.
LS:NOS
|
$1.95 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Novocure Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 360,179,000 to 340,466,000, a change of -19,713,000 (-5.5%).
- Net loss of 136,227,000 reduced equity.
- New share issuances of 3,656,000 increased equity.
- Other comprehensive income increased equity by 2,059,000.
- Other factors increased equity by 110,799,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-136.23 Million | -40.01% |
| Share Issuances | $3.66 Million | +1.07% |
| Other Comprehensive Income | $2.06 Million | +0.6% |
| Other Changes | $110.80 Million | +32.54% |
| Total Change | $- | -5.47% |
Book Value vs Market Value Analysis
This analysis compares Novocure Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.84x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 1.25x to 5.84x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $14.27 | $17.85 | x |
| 2014-12-31 | $1.36 | $17.85 | x |
| 2015-12-31 | $3.00 | $17.85 | x |
| 2016-12-31 | $1.66 | $17.85 | x |
| 2017-12-31 | $1.28 | $17.85 | x |
| 2018-12-31 | $1.22 | $17.85 | x |
| 2019-12-31 | $2.24 | $17.85 | x |
| 2020-12-31 | $4.38 | $17.85 | x |
| 2021-12-31 | $3.97 | $17.85 | x |
| 2022-12-31 | $4.22 | $17.85 | x |
| 2023-12-31 | $3.41 | $17.85 | x |
| 2024-12-31 | $3.34 | $17.85 | x |
| 2025-12-31 | $3.05 | $17.85 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Novocure Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -40.01%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -20.79%
- • Asset Turnover: 0.81x
- • Equity Multiplier: 2.36x
- Recent ROE (-40.01%) is above the historical average (-42.60%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -45.04% | -746.89% | 0.05x | 1.10x | $-94.55 Million |
| 2014 | -82.43% | -520.87% | 0.13x | 1.20x | $-90.47 Million |
| 2015 | -44.49% | -337.24% | 0.11x | 1.23x | $-136.66 Million |
| 2016 | -92.62% | -159.06% | 0.29x | 1.98x | $-146.08 Million |
| 2017 | -54.30% | -34.83% | 0.67x | 2.34x | $-73.02 Million |
| 2018 | -56.62% | -25.62% | 0.73x | 3.03x | $-74.78 Million |
| 2019 | -3.32% | -2.06% | 0.73x | 2.20x | $-29.01 Million |
| 2020 | 4.16% | 4.01% | 0.47x | 2.21x | $-27.84 Million |
| 2021 | -14.21% | -10.91% | 0.47x | 2.78x | $-99.40 Million |
| 2022 | -20.97% | -17.20% | 0.45x | 2.70x | $-136.65 Million |
| 2023 | -57.12% | -40.65% | 0.44x | 3.16x | $-243.29 Million |
| 2024 | -46.82% | -27.86% | 0.49x | 3.44x | $-204.64 Million |
| 2025 | -40.01% | -20.79% | 0.81x | 2.36x | $-170.27 Million |
Industry Comparison
This section compares Novocure Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $1,818,520,110
- Average return on equity (ROE) among peers: -48.87%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Novocure Ltd (NVCR) | $330.72 Million | -45.04% | 1.38x | $1.95 Billion |
| Abbott Laboratories (ABT) | $17.78 Billion | 20.28% | 1.23x | $153.89 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $19.91 Million | -270.00% | 1.43x | $15.55 Million |
| Aethlon Medical Inc (AEMD) | $-5.98 Million | 0.00% | 0.00x | $2.51 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $903.35K |
| Adapthealth Corp (AHCO) | $280.85 Million | -57.55% | 5.46x | $1.29 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $6.89 Million | 30.07% | 0.49x | $6.67 Million |
| Allurion Technologies, Inc. (ALUR) | $-70.49 Million | 0.00% | 0.00x | $7.70 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $8.10 Million | -140.88% | 0.21x | $4.44 Million |
| Artivion Inc (AORT) | $17.90 Million | 7.26% | 0.20x | $1.03 Billion |
| Apyx Medical Inc (APYX) | $22.89 Million | 2.69% | 0.23x | $176.29 Million |
About Novocure Ltd
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TT… Read more